News and Community

Chief Medical Officer, Drug Administration, Genentech, Healthcare Technology, Kras G12c, Oncology

July 2, 2026

Genentech’s Divarasib Proves Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Aav-based Gene Therapies, Domestic Pharmaceutical, Drug Administration, Drug Supply Chain, Healthcare Technology, Pilot Program

June 30, 2026

FDA Chooses Kriya Therapeutics for Next-Generation Medical Pilot Program